Short Communication

Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, Rome, 00133, Italy

Search for more papers by this author

Cinzia Ciccacci

*Author for correspondence:

E-mail Address: cinziaciccacci@libero.it

https://orcid.org/0000-0002-3995-7032

UniCamillus, Saint Camillus International University of Health Sciences, Rome, 00131, Italy

Search for more papers by this author

Giuseppe Novelli

https://orcid.org/0000-0002-7781-602X

Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, Rome, 00133, Italy

IRCCS NEUROMED, Pozzilli, IS, 86077, Italy

School of Medicine, Department of Pharmacology, Reno University of Nevada, NV 89557, USA

Search for more papers by this author

Vincenza Spallone‡

Department of Systems Medicine, Endocrinology Section, University of Rome Tor Vergata, Rome, 00133, Italy

‡These authors contributed equally to this work

Search for more papers by this author

Paola Borgiani‡

Department of Biomedicine & Prevention, Genetics Section, University of Rome Tor Vergata, Rome, 00133, Italy

‡These authors contributed equally to this work

Search for more papers by this author

Published Online:15 Jan 2024https://doi.org/10.2217/epi-2023-0320

View article

Abstract

Background & aims: This study investigated a possible correlation between three circulating miRNAs, previously observed to be associated to diabetic polyneuropathy, and the obesity condition. Methods & results: The expression levels of miR-128a, miR-155 and miR499a were evaluated in 49 participants with Type 2 diabetes, divided into different groups based on the presence or absence of obesity and central obesity. The analyses revealed a significant decrease of miR-155 and miR-499a expression levels in obese subjects. In particular, the reduction appears to be even more significant in Type 2 diabetes subjects with central obesity. Conclusion: The results suggest that these miRNAs could be involved in obesity-driven pathogenetic mechanisms.

Keywords:

Papers of special note have been highlighted as: • of interest

References

1. Pillon NJ, Loos RJF, Marshall SM, Zierath JR. Metabolic consequences of obesity and Type 2 diabetes: balancing genes and environment for personalized care. Cell 184(6), 1530–1544 (2021).
Medline CASGoogle Scholar
2. Lee JJ, Beretvas SN, Freeland-Graves JH. Abdominal adiposity distribution in diabetic/prediabetic and nondiabetic populations: a meta-analysis. J. Obes. 2014, 697264 (2014).
MedlineGoogle Scholar
3. Landrier JF, Derghal A, Mounien L. MicroRNAs in obesity and related metabolic disorders. Cells 8(8), 859 (2019).
Medline CASGoogle Scholar
4. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. (Lausanne) 9, 402 (2018).
MedlineGoogle Scholar
5. Kim M, Zhang X. The profiling and role of miRNAs in diabetes mellitus. J. Diabetes Clin. Res. 1(1), 5–23 (2019). • Reviews the role of miRNAs in diabetes.
MedlineGoogle Scholar
6. Ciccacci C, Latini A, Colantuono A et al. Expression study of candidate miRNAs and evaluation of their potential use as biomarkers of diabetic neuropathy. Epigenomics 12(7), 575–585 (2020). • Describes the association between miR-128, miR-155 and miR499a and diabetic neuropathy susceptibility.
CASGoogle Scholar
7. Mahesh G, Biswas R. MicroRNA-155: a master regulator of inflammation. J. Interferon Cytokine Res. 39(6), 321–330 (2019).
Medline CASGoogle Scholar
8. Yang P, Han J, Li S, Luo S, Tu X, Ye Z. miR-128-3p inhibits apoptosis and inflammation in LPS-induced sepsis by targeting TGFBR2. Open Med. (Wars.) 16(1), 274–283 (2021).
Medline CASGoogle Scholar
9. Wan Q, Xu T, Ding W et al. miR-499-5p attenuates mitochondrial fission and cell apoptosis via p21 in doxorubicin cardiotoxicity. Front. Genet. 9, 734 (2019).
MedlineGoogle Scholar
10. Chen C, Deng Y, Hu X et al. miR-128-3p regulates 3T3-L1 adipogenesis and lipolysis by targeting Pparg and Sertad2. J. Physiol. Biochem. 74(3), 381–393 (2018).
Medline CASGoogle Scholar
11. Wang L, Zhang N, Wang Z, Ai DM, Cao ZY, Pan HP. Decreased miR-155 level in the peripheral blood of non-alcoholic fatty liver disease patients may serve as a biomarker and may influence LXR activity. Cell Physiol. Biochem. 39(6), 2239–2248 (2016).
Medline CASGoogle Scholar
12. Smith AG, Singleton JR. Diabetic neuropathy. Continuum 18(1), 60–84 (2012).
MedlineGoogle Scholar
13. Tesfaye S, Chaturvedi N, Eaton SE et al. Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 352(4), 341–350 (2005).
Medline CASGoogle Scholar
14. Gabir MM, Hanson RL, Dabelea D et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23(8), 1108–1112 (2000).
Medline CASGoogle Scholar
15. Lodhi IJ, Semenkovich CF. Peroxisomes: a nexus for lipid metabolism and cellular signaling. Cell Metab. 19(3), 380–392 (2014).
Medline CASGoogle Scholar
16. Hallenborg P, Jensen BAH, Fjære E et al. Adipose MDM2 regulates systemic insulin sensitivity. Sci. Rep. 11(1), 21839 (2021).
Medline CASGoogle Scholar
17. Tryggestad JB, Teague AM, Sparling DP, Jiang S, Chernausek SD. Macrophage-derived microRNA-155 increases in obesity and influences adipocyte metabolism by targeting peroxisome proliferator-activated receptor gamma. Obesity (Silver Spring) 27(11), 1856–1864 (2019).
Medline CASGoogle Scholar
18. Mahdavi R, Ghorbani S, Alipoor B et al. Decreased serum level of miR-155 is associated with obesity and its related metabolic traits. Clin. Lab. 64(1), 77–84 (2018).
Medline CASGoogle Scholar
19. Cerda A, Amaral AA, de Oliveira R et al. Peripheral blood miRome identified miR-155 as potential biomarker of MetS and cardiometabolic risk in obese patients. Int. J. Mol. Sci. 22(3), 1468 (2021). • Reveals that miR-155 regulates the expression of genes involved in adipogenesis.
Medline CASGoogle Scholar
20. Lin X, Qin Y, Jia J et al. miR-155 enhances insulin sensitivity by coordinated regulation of multiple genes in mice. PLOS Genet. 12, e1006308 (2016).
MedlineGoogle Scholar
21. Latini A, Spallone V, D'Amato C, Novelli G, Borgiani P, Ciccacci C. A common polymorphism in MIR155 gene promoter region is associated with a lower risk to develop Type 2 diabetes. Acta Diabetol. 56(6), 717–718 (2019).
Medline CASGoogle Scholar
22. Xie K, Ma H, Liang C et al. A functional variant in miR-155 regulation region contributes to lung cancer risk and survival. Oncotarget 6, 42781–42792 (2015).
MedlineGoogle Scholar
23. Deddens JC, Colijn JM, Oerlemans MI et al. Circulating microRNAs as novel biomarkers for the early diagnosis of acute coronary syndrome. J. Cardiovasc. Transl. Res. 6(6), 884–898 (2013).
Medline CASGoogle Scholar
24. Giuliani A, Montesanto A, Matacchione G et al. The association between single nucleotide polymorphisms, including miR-499a genetic variants, and dyslipidemia in subjects treated with pharmacological or phytochemical lipid-lowering agents. Int. J. Mol. Sci. 23(10), 5617 (2022). • Describes the association between MIR499a polymorphism and blood lipid profile.
Medline CASGoogle Scholar
25. Chen LB, Zheng HK, Zhang L et al. A single nucleotide polymorphism located in microRNA-499a causes loss of function resulting in increased expression of osbpl1a and reduced serum HDL level. Oncol. Rep. 38(6), 3515–3521 (2017).
Medline CASGoogle Scholar
26. Wang JX, Jiao JQ, Li Q et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat. Med. 17(1), 71–78 (2011).
MedlineGoogle Scholar
27. Afshinnia F, Reynolds EL, Rajendiran TM et al. Serum lipidomic determinants of human diabetic neuropathy in Type 2 diabetes. Ann. Clin. Transl. Neurol. 9(9), 1392–1404 (2022).
Medline CASGoogle Scholar
28. Elafros MA, Andersen H, Bennett DL et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 21(10), 922–936 (2022).
MedlineGoogle Scholar
29. Spallone V, Ciccacci C, Latini A, Borgiani P. What is in the field for genetics and epigenetics of diabetic neuropathy: the role of microRNAs. J. Diabetes Res. 2021, 5593608 (2021).
Medline CASGoogle Scholar

Vol. 16, No. 2

Supplemental Materials

Metrics

Downloaded 11 times

History

Received 7 September 2023

Accepted 21 December 2023

Published online 15 January 2024

Published in print January 2024

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/epi-2023-0320

Author contributions

Conceptualization: P Borgiani, C Ciccacci; data curation: A Latini, G De Benedittis; formal analysis: A Latini, G De Benedittis; funding acquisition: G Novelli; investigation: A Latini, G De Benedittis; methodology: A Latini, G De Benedittis; project administration: G Novelli; resources: V Spallone; supervision: V Spallone, P Borgiani; validation: C Ciccacci; roles/writing – original draft: A Latini; writing – review and editing: C Ciccacci, V Spallone, P Borgiani.

Financial disclosure

This study was supported by a grant of “Piano Sviluppo e Coesione Salute” (FSC 2014-2020. T3-AN-04 GENERA) and by a grant of European Union – NextGenerationEU, PNRR M4-C2-1.4 (CN00000041) to G Novelli. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. All participants provided written informed consent. The study was approved by the Ethics Committee of the University Hospital of Rome Tor Vergata (approval no. 2936/2017).

Data sharing statement

Data will be made available on request.

PDF download

Low expression levels of miRNA-155 and miRNA-499a are associated with obesity in Type 2 diabetes

Abstract

References